Invisible virus is being evaluated as the next generation of compassionate cancer cures
August 10, 2012
The investigative FOXNews journalists caught up with the clinicians, nurses and researchers at California Veterinary Specialists Angel Care Cancer Center to learn how an invisible virus is being evaluated as the next generation of compassionate cancer cures in dogs, cats and people. Angel Care Cancer Center, a separate but allied non-profit research organization, the Special Care Foundation for Companion Animals and the San Diego based company Genelux have teamed up to affirm the safety an efficacy of a new cancer killing virus. The therapy includes a modification of a virus that has been used worldwide to wipe out smallpox as a threat to human health. Families who bring their beloved pets with cancer to Angel Care seek the highest level of advanced yet gentle cancer care and novel, new therapies that are likely to become the therapies of the future. The purpose of the study is to determine the optimum way of treating these dogs with cancer while taking these results to develop new approaches to enhance the cure rates in children and adults.
The CVS Angel Care Cancer Center is a comprehensive cancer center that provides direct care for patients with cancer and their families. This team offers innovative clinical research to provide the very best diagnostics and treatments available to fight against cancer. They are a group of veterinarians, veterinary nurses, and human physicians that share a mutual philosophy: science may provide a cure, but compassionate care comes from the heart. The goal is to do everything possible to not only win the fight against cancer, but to ensure the treatment is healing, not hurting.
Come join us on Saturday, February 22, and support the San Diego K9 Cancer Walk Benefiting Morris Animal Foundation to help find a cure. California Veterinary Specialists will be there in full support of the Morris Foundation and will have a team walking as well. Our team name is Angel Care for the Cure and our Team Capitan is Leah Larscheidt. Please help support our team by joining us for the walk, donating to our team or just coming out to cheer us on. We hope to see you there!
There are currently very promising developments in the treatment of canine cancer that focus on the natural immune response of the body. Cancer cells secrete elements into the blood that inhibit the immune system from killing them. The LW-2 Canine Therapy focuses on removing these harmful elements without the use of drugs, chemicals, radiation, or complicated surgical procedures. This approach is also intended to limit the possibilities and side effects traditionally associated with cancer treatments.
MURRIETA, CALIF. — California Veterinary Specialists Angel Care Center (CVS Angel Care) was named March Business of the Month by Assemblywoman Melissa Melendez for the Center’s canine cancer clinical trials using Voyager, a new and revolutionary non-invasive anti-cancer medical device. “We are overjoyed to receive this award from Assemblywoman Melendez for our work to eliminate cancer in pets,” said Dr. Greg Ogilvie, founder of CVS Angel Care. “Voyager has the potential to save hundreds of thousands of lives and has given families of...
We are in a process developing a new therapy for dogs with lymphoma that harnesses the immune system to destroy its own cancer. With appropriate therapy we are able to not only enhance and improve their quality of life but also extend that life and reduce the need for chemotherapy. This non-invasive, fully-funded study is one in which we take animals that have lymphoma and willing families who are excited about exploring new opportunities that will enhance and improve the quality of life of a pet with cancer. The veterinary health team...
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer PatientsMay 31, 2012
SAN DIEGO, May 31,2012 -- Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best–in-class vaccinia virus based oncolytic viral therapies and companion diagnostics for human cancer patients, today announced the start of a ground-breaking clinical study involving the oncolytic Vaccinia virus V-VET1 in canine cancer patients with various measurable malignancies. Although oncolytic viruses are being more extensively evaluated in humans, this study is the first of its kind